CDEK
← All drugs Report issue

DP303c

mAbexperimental

Clinical trial activity

9 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
7
Phase 3
2
Phase 4
0

Earliest trial started Nov 30, 2019 (NCT04146610)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07241936Phase 1/Phase 2 (Phase 2)Nov 13, 2025Shijiazhuang Pharma Group (CSPC)
NCT06577376Phase 1/Phase 2 (Phase 2)Aug 26, 2024—
NCT06313086Phase 3Mar 13, 2024Shijiazhuang Pharma Group (CSPC)
NCT05901935Phase 3Jul 31, 2023Shijiazhuang Pharma Group (CSPC)
NCT05810103Phase 1Apr 6, 2023Shijiazhuang Pharma Group (CSPC)
NCT05334810Phase 2May 1, 2022Shijiazhuang Pharma Group (CSPC)
NCT04826107Phase 2Aug 31, 2021People's Liberation Army of China, Shijiazhuang Pharma Group (CSPC)
NCT04828616Phase 2Jul 31, 2021Shijiazhuang Pharma Group (CSPC)
NCT04146610Phase 1Nov 30, 2019Shijiazhuang Pharma Group (CSPC)
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Shijiazhuang Pharma Group (CSPC)For profit8832019
People's Liberation Army of ChinaGovernment1012021
2 organizations
Page 1 / 1